This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Signifor
  • /
  • Long Term Safety and Efficacy of Pasireotide s.c. ...
Clinical trial

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Read time: 3 mins
Last updated:28th Mar 2013
Identifier: NCT02310269

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.


Study Type: Observational
Estimated Enrollment: 200 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)
Actual Study Start Date: March 28, 2013
Estimated Primary Completion Date: September 27, 2023
Estimated Study Completion Date: September 27, 2023

Group/Cohort:
- Pasireotide

Category Value
Date last updated at source 2019-07-18
Study type(s) Observational study
Expected enrolment 200
Study start date 2013-03-28
Estimated primary completion date 2023-09-27

View full details